Yaron Pereg

Yaron Pereg

Company: Kahr Medical

Job title: CEO


DSP107, a First-in-Class CD47x41BB Targeting Fusion Protein, Activates Both – Innate and Adaptive Immunity 2:00 pm

Second generation CD47 targeting compound with a best in class profile Unique mechanism of action – activates both the innate and the adaptive immune systems Excellent safety profile without hematological toxicitiesRead more

day: Clinical Development - Day 1 pm

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.